What are the 2026 cholesterol management guidelines, including recommended screening age, risk assessment tools, LDL‑C target levels, and treatment recommendations such as statin intensity, ezetimibe, PCSK9 inhibitors, coronary calcium scoring, and management of elevated triglycerides and lipoprotein(a)?

2026 Cholesterol Management Guidelines

The 2026 ACC/AHA guidelines represent the most current evidence-based approach to dyslipidemia management, emphasizing risk-stratified LDL-C targets, early combination therapy, and expanded use of coronary artery calcium scoring to guide treatment decisions. 1

Screening and Risk Assessment

Initial Screening

• Obtain a lipid panel at age 40 or at diabetes diagnosis, then every 5 years if under age 40 and not on therapy 2
• Use PREVENT equations for 10-year ASCVD risk estimation in primary prevention (replacing the older Pooled Cohort Equations with lower risk thresholds) 3
• Consider SCORE2 for adults and SCORE2-OP for older persons as alternative validated risk calculators 4, 5

Risk Modifiers and Enhanced Assessment

• Risk-enhancing factors include: family history of premature ASCVD, persistently elevated LDL-C ≥160 mg/dL, metabolic syndrome, chronic kidney disease, preeclampsia/premature menopause, chronic inflammatory disorders (rheumatoid arthritis, psoriasis, HIV), South Asian ancestry, persistent triglycerides ≥175 mg/dL, apolipoprotein B ≥130 mg/dL, hs-CRP ≥2.0 mg/L, ABI <0.9, and lipoprotein(a) ≥50 mg/dL 6

Coronary Artery Calcium (CAC) Scoring

• Use CAC scoring in adults 40-75 years with borderline to intermediate 10-year ASCVD risk (5-20%) when treatment decision is uncertain 6, 7
• If CAC = 0: Consider deferring statin therapy for 5 years with focus on lifestyle modifications (except in smokers, diabetics, or those with strong family history) 6, 8
• If CAC 1-99: Favors statin therapy, especially age ≥55 years 6, 8
• If CAC ≥100 or ≥75th percentile: Initiate statin therapy 6, 8
• If CAC ≥1000: Use high-intensity statin therapy with guideline-based add-on therapies (ezetimibe, PCSK9 inhibitors) to achieve ≥50% LDL-C reduction and optimally LDL-C <70 mg/dL 7

LDL-C Treatment Targets by Risk Category

Very High Risk (Secondary Prevention + High-Risk Features)

Target: LDL-C <55 mg/dL AND ≥50% reduction from baseline 8, 9, 2

Very high-risk includes:

• Clinical ASCVD with additional high-risk features (recent ACS, multiple vascular beds, diabetes with target organ damage) 8
• Diabetes with ASCVD 2
• Severe chronic kidney disease (eGFR 15-29 mL/min) 8

High Risk

Target: LDL-C <70 mg/dL AND ≥50% reduction from baseline 8, 9, 2

High-risk includes:

• Clinical ASCVD (prior MI, ACS, coronary/arterial revascularization, stroke, TIA, PAD) 6
• Diabetes age 40-75 with additional ASCVD risk factors 2
• LDL-C ≥190 mg/dL (severe primary hypercholesterolemia) 6
• 10-year ASCVD risk ≥20% 6

Moderate Risk

Target: LDL-C <100 mg/dL 8, 9

Moderate-risk includes:

• Diabetes age 40-75 without additional risk factors 2
• 10-year ASCVD risk 7.5-19.9% 6

Low Risk

Target: LDL-C <116 mg/dL 8, 9

Statin Therapy Recommendations

High-Intensity Statins (Lower LDL-C by ≥50%)

• Atorvastatin 40-80 mg daily 2
• Rosuvastatin 20-40 mg daily 2

Moderate-Intensity Statins (Lower LDL-C by 30-49%)

• Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg, Simvastatin 20-40 mg, Pravastatin 40-80 mg, Lovastatin 40 mg, Fluvastatin XL 80 mg, Pitavastatin 1-4 mg 2

Specific Populations

Diabetes without ASCVD:

• Age 40-75: Moderate-intensity statin (Class I/A) 2
• Age 40-75 with high risk: High-intensity statin to achieve ≥50% LDL-C reduction and target <70 mg/dL (Class I/B) 2
• Age 20-39 with additional risk factors: Consider statin therapy (Class IIa/C) 2
• Age >75 already on statin: Continue therapy (Class IIa/B) 2
• Age >75 not on statin: Consider moderate-intensity statin after risk-benefit discussion (Class IIb/C) 2

Diabetes with ASCVD:

• High-intensity statin targeting ≥50% LDL-C reduction and goal <55 mg/dL (Class I/A) 2

Severe Primary Hypercholesterolemia (LDL-C ≥190 mg/dL):

• High-intensity statin without calculating 10-year risk 6

Primary Prevention (no diabetes, LDL-C ≥70 mg/dL):

• 10-year risk ≥7.5%: Moderate-intensity statin if risk discussion favors therapy 6
• 10-year risk ≥20%: Reduce LDL-C by ≥50% 6

Adding Ezetimibe

Very High Risk Patients

Add ezetimibe when LDL-C remains ≥70 mg/dL on maximally tolerated statin (Class IIa) 8, 6, 8

High Risk Patients (Including Diabetes with ASCVD)

Add ezetimibe when LDL-C remains ≥70 mg/dL on maximally tolerated statin 10, 2

Severe Primary Hypercholesterolemia

Add ezetimibe if LDL-C remains ≥100 mg/dL on statin (Class IIa) 6, 8

Practical Considerations

• Take ezetimibe once daily, with or without food 11
• If taking bile acid sequestrant, take ezetimibe at least 2 hours before or 4 hours after 11
• Monitor liver enzymes and watch for unexplained muscle pain 11

Adding PCSK9 Inhibitors

Very High Risk Patients

Add PCSK9 inhibitor when LDL-C remains ≥70 mg/dL on maximally tolerated statin + ezetimibe (Class IIa) 8, 6, 8

Diabetes with ASCVD

Add PCSK9 inhibitor if LDL-C goal <55 mg/dL not achieved on maximum tolerated statin + ezetimibe (Class I/B) 2

Severe Primary Hypercholesterolemia

Consider PCSK9 inhibitor if LDL-C remains ≥100 mg/dL on statin + ezetimibe with multiple ASCVD risk factors (Class IIb) 6

Heterozygous Familial Hypercholesterolemia

Add PCSK9 inhibitor if LDL-C ≥100 mg/dL on maximum tolerated statin + ezetimibe (Class IIb for primary prevention, Class I/C for secondary prevention) 8

Primary Prevention (Very Select Cases)

Consider PCSK9 inhibitor in age 40-75 with baseline LDL-C ≥220 mg/dL on maximum tolerated statin + ezetimibe if LDL-C remains ≥130 mg/dL (Class IIb/C-LD) 8

Important Limitations

• Long-term safety beyond 3 years remains uncertain 6
• Cost-effectiveness is low at current pricing 6
• No indication for PCSK9 inhibitors in diabetes without clinical ASCVD 8

Acute Coronary Syndrome Management

Initiate high-dose statin immediately upon admission in all ACS patients without contraindication, regardless of initial LDL-C values (Class I) 9, 4, 5

Consider immediate combination therapy with statin + ezetimibe for intensive LDL-C lowering in recent ACS 12, 5

Alternative and Adjunctive Therapies

Bempedoic Acid

Consider adding bempedoic acid if further LDL-C reduction needed after statin + ezetimibe, or as alternative in statin-intolerant patients 12, 13, 5

Inclisiran

Consider inclisiran (siRNA PCSK9 inhibitor) for high/very high-risk patients requiring additional LDL-C lowering, with advantage of twice-yearly dosing 5

Bile Acid Sequestrants

Consider as add-on therapy if <50% LDL-C reduction in patients with baseline LDL-C ≥190 mg/dL and triglycerides <300 mg/dL (Class IIb) 8

Elevated Triglycerides Management

Moderate Hypertriglyceridemia (135-499 mg/dL)

Consider icosapent ethyl in high/very high-risk patients with triglycerides 135-499 mg/dL despite statin therapy (Class IIa per ESC/EAS) 8

Severe Hypertriglyceridemia (≥500 mg/dL)

Consider fibrate therapy when fasting triglycerides ≥500 mg/dL (especially ≥1000 mg/dL) to reduce pancreatitis risk, in addition to addressing other risk factors (Class IIa) 8

Implement moderate dietary fat restriction (25-30% calories from fat, ideally ≤40-50 grams/day) 12

Lifestyle Modifications

Lifestyle modifications (weight loss, reduced refined carbohydrates, increased physical activity) are often more effective than specific triglyceride-lowering medications 13

Lipoprotein(a) Management

Measurement Indications

Measure Lp(a) in patients at high risk of CVD, targeting levels <50 mg/dL 9

Treatment Considerations

Patients with elevated Lp(a) may have greater ASCVD risk reduction with PCSK9 inhibitors and should be prioritized for this therapy 3

Lp(a) ≥50 mg/dL (especially higher values) is a risk-enhancing factor favoring statin therapy in intermediate-risk patients 6

Monitoring and Follow-Up

Assess LDL-C 4-12 weeks after statin initiation or dose adjustment, then every 3-12 months as needed 6, 2

Continue cholesterol-lowering diet and exercise program throughout treatment 11

Use maximum tolerated statin dose if intended intensity not tolerated 2

Common Pitfalls to Avoid

• Do not defer treatment in high-risk patients solely based on age >75 years—continue or initiate therapy with careful risk-benefit discussion 2
• Do not use low-intensity statins unless higher doses are not tolerated—they provide insufficient LDL-C reduction 8
• Do not add PCSK9 inhibitors before maximizing statin + ezetimibe therapy (except in specific high-risk scenarios) 10, 6
• Do not ignore CAC scoring in borderline/intermediate-risk patients—it significantly improves risk stratification and treatment allocation 7, 3
• Do not target LDL-C goals without considering absolute ASCVD risk—treatment intensity should match risk level 10
• Do not use fibrates as first-line therapy for LDL-C lowering—statins remain first-line 8